May 16, 2020 12:13pm

A scorecard of 29 (added PSTI) earnings "confessions", 1 restatement and 1 acquisition of 35 covered  companies

The current LPS (loss per share) or net income, cash positions i.e. "runways"  is a reflection of this universe's investing "status"

 


COMPANY 

SYMBOL NET INCOME Q1/20 LOSS Q1/20 LPS Q1/20 CASH RUNWAY
Aduro Biotech, Inc. ADRO   -$7.6 M -$0.09 $205.9 M  early 2023
Alnylam Pharmaceuticals ALNY   -$182 M -$1.62 $1.37 Billion 2025
Applied Genetic Technologies AGTC  

-$11.2 M

(Q3)

-$0.50 $84.5 M 2021
Athersys, Inc. ATHX   -$15.6 M -$0.10

$32.7 M EOY

+$57.6 M

offering

2022
Adverum Biotechnologies, Inc. ADVM          
AxoGen, Inc. AXGN   -$8.19 M -$0.21 $89 M 2021
Bellicum Pharmaceuticals BLCM

$17.57 M or

+$1.09

    $75.5 M 2H/2021
BioLife Solutions, Inc. BLFS

+$22.3 M or

+$0.87

   

$6.4 M +

$12.2 M revenue

$20 M from 

Casdin Capital ++

2022
Biostage, Inc. BSTG   -$2 M -$0.24 $800 K Q3/2020
bluebird bio BLUE   -$202.6 M -$3.64 $1.02 Billion 2022
Brainstorm Cell Therapeutics BCLI   -$8.1 M -$0.31

$14.5 M +

$50 ATM

2021
Caladrius Biosciences. CLBS   -$4 M -$0.38

$34 M from

RDO + 

sales of NOLs

Q2/2021

Cellectis SA CLLS

+$20 M

+$0.47

    $351 M 2022
CRISPR Therapeutics CRSP   -$69.7 M -$1.15 $889.7 M 2022
Editas Medicine EDIT   -$37.7 M -$0.69 $415 M Q1/2021
Fate Therapeutics FATE   -$33.5 M -$0.44

$219 M

$100 M

Janssen/J&J 

collab

2022
Global Blood Therapeutics GBT   -$73 M  -$1.20 $615 M 2022
Homology Medicine FIXX   -$35.3 M -$0.78 $234.9 M Q4/2021
Intellia Therapeutics NTLA   -$31.8 M -$0.63 $250.3 M Q1/2021

Precigen

formerly

Intrexon Corporation

PGEN          
Ionis Pharmaceuticals IONS

+$59 M

+$0.35

    $2.4 M 2025
Mesoblast Limited MESO          
MiMedx Group, Inc

OTC PINK:

MDXG

Restating        
Pluristem Therapeutics, Inc. PSTI   -$21 M -$1.28

$6.7 M

$US$64.93 M +

$15 M raise

2022
ReNeuron Group PLC RENE.L          
Regenxbio RGNX   -$40 M -$1.08 $356.6 M 2022
Sage Therapeutics SAGE   -$126.& M -$2.44 $900 M 2022
Sangamo Biosciences, Inc. SGMO   -$42.9 M -$0.37

$384 M+

$350 M

BIIB collab

2023
Solid Biosciences SLDB   -$26.94 M -$0.56 $53.8 M Q1/2021
Stemline Therapeutics, Inc. STML

Acquired by

Menarini, an

Italian pharma

       
Ultragenyx RARE   -$119 M -$2.05 $705 M 2022
uniQure N.V. QURE   -$28 M -$0.63 $342 M 2022
Verastem, Inc. VSTM   -$38 M -$0.35

$170 .7 M

with

PP of $93.8 M

2022
Vericel Corporation VCEL   -$4.7 M -$0.10 $83.3 M 2022
Voyager Therapeutics VYGR   -$24.3 M -$0.66 $250.9 M 2022